Data Insights: Identifying Early Signs of Safety and Efficacy in Oncology Clinical Trials
The Dynamic Trial: Is It the Right Option for You?
Efficient Data Management: One Way to Expedite the Clinical Development Process
Many Drugs Don't Move Past Phase I. Will Yours?
CAR T-Cell Therapy: Revolutionizing Cancer Treatment
The Quick-Start Guide to Clinical Strategy
6 Signs You Need a New CRO for Your Preclinical Research
The A-Z Guide of DMPK Assays and How to Find the Right One
The Trends Behind Successful Cancer Treatments
Laidlaw Venture Partners Portfolio Company Voltron Therapeutics Enters into Strategic Development Agreement With Translational Drug Development (TD2), a Precision Oncology Contract Research Organization (CRO)
November 24, 2020
TD2 and VieCure Partner to Bring Best-in-Class Cancer Medicines and Access to Precision Oncology Clinical Trials to Patients in Community Oncology Practices
October 29, 2020
Applied Clinical Trials: Small Biopharma and CROs: Seeking Stronger Synergies
September 28, 2020
Ready to Make an Impact? Join Our Team.
July 16, 2020
PM360: COVID-19’s Long-Lasting Impact on Clinical Trials
June 16, 2020
RCT Acquires Translational Drug Development, LLC
June 04, 2020
TD2 Business Continuity during COVID-19
March 25, 2020
BioSpace: What Does 2020 Have in Store for Life Sciences?
January 16, 2020
Genzada Pharmaceuticals Doses First Patient
April 10, 2019